New CAD-RADS 2.0 reporting for coronary CTA offers patient management recommendations

Examples of new plaque reporting in the CAD-RADS 2.0 document. Left, an example from CAD-RADS 2 / P2 plaque burden with mild coronary stenosis (25-49%). Right, example of a CAD-RADS 5/ P3, with a focal, non-calcified occlusion of the proximal RCA (arrow) and severe amount of plaque (P3). #CADRADS #YesCCT #CTA #CCTA
Examples of new plaque reporting in the CAD-RADS 2.0 document. Left, an example from CAD-RADS 2 / P2 plaque burden with mild coronary stenosis (25-49%). Right, example of a CAD-RADS 5/ P3, with a focal, non-calcified occlusion of the proximal RCA (arrow) and severe amount of plaque (P3).

The document includes updated classification to established a framework for stenosis, plaque burden and plaque modifiers, including assessment of CT-FFR or myocardial CT perfusion.

U.S. expected to see large rise in cardiomyopathy cases over next decade

The projected number of acquired cardiomyopathy cases are expected to greatly outpace the number of new familial cardiomyopathy cases by 2031 in the U.S., driven mainly by poor lifestyles. This is expected to have a big impact on healthcare.
The projected number of acquired cardiomyopathy cases are expected to greatly outpace the number of new familial cardiomyopathy cases by 2031 in the U.S., driven mainly by poor lifestyles. This is expected to have a big impact on healthcare in the next decade.

“Even if we compensate for the differences in population size, the U.S. is still miles ahead when it comes to total cardiomyopathy cases," explained Walter Gabriel, MPH, an epidemiologist and analyst on the report.